Team:Nanjing high school/Implementation


End Users
    Studies have shown that an Alzheimer’s patient is born every three seconds. As of 2019, more than 52 million people worldwide are living with Alzheimer’s disease. The patients in China achieved a quarter of the total. In the same year, an expert in Alzheimer’s research in the United States said,” They're maybe more people who go undiagnosed. Nowadays millions of people worldwide are suffered from the pain of Neurodegenerative diseases (NIH) and currently, no one in the world can completely cure these kinds of diseases, all we can do is slow down the process.
So our product is targeting those patients who suffer from the disease related to the microglia Inflammation, such as Alzheimer’s.
Product Theory
    We screened out the most effective PPM1A enzymatic activator compound V through phosphatase enzyme activity assay with pNPP as the substrate. Then, we use qPCR assay and proved the inhibitive effect of compound 5 against PPM1A. As a result, compound 5 was demonstrated as a PPM1A activator and its anti-inflammatory effect was determined. We will investigate the regulation of PPM1A against inflammation and the diseases related to inflammation in future scientific research work. Our drug will be the first to actually fight diseases like Alzheimer’s and Parkinson’s that are caused by inflammation. This is unprecedented in the global pharmaceutical market!
Product Commercialization
*Creative Commons licensed image from Bing
Taking a small pill could save the patients from the pain of forgetting. Taking a small pill could warm up a family that has been hurt before. In addition, our team will try to get this drug to Medicare. This means that the cost of the drug will be much lower. In this way, the financial burdens of the patients' families are greatly reduced. Our products should be extraordinarily profitable if we successfully invented them, as there is no substitute in the market to cure those diseases.
    Our market is tremendous, and the number of consumers is also increasing. In addition, problems caused by Neurodegenerative diseases have become severer as technology becomes more developed and the life expectancy becomes longer, especially nowadays the whole world is facing the problem of the aging population. For example, until 2015, 26% of Japan’s population is over 65 years old, which means a quarter of the population is elder (Paola Scommegna). National Institute of Health predicted that there will be 1.6 billion elders worldwide when we reach 2050. Elders are assumed to be the group of people who are most likely to suffer a special neurodegenerative disease: Alzheimer’s disease. According to the website called Alzheimer’s news today, there is approximately 44 million patient in worldwide who have Alzheimer’s diseases. In the future, the problem of an aging population will become severer and the need for our product will grow in the same step.
    After Drug R & D is completed, we are ready to commercialize the drug according to the business plan we wrote. Specifically, we will cooperate with major hospitals and pharmacies. Then we can sell our medicines online and offline through these institutions. Furthermore, we will also plan to add our drugs to the medical insurance list to reduce the financial burden of our stakeholders, and more people can use our medicines and increase the sales of drugs.
Expert Consultant
    Moreover, after we interviewed professor Lu, we have determined our stakeholders and changed the position of our product, because we were planning to do a health product that is helpful for people who are suffering from Neuroinflammation. However, according to professor Lu, she said that producing health products straight is impossible since the rules made by the State Food and Drug Administration are strict. This will cause people to ignore the side effects of pharmaceutical products. Thus, we changed our product from a health product into medicine. Meanwhile, the age range of our stakeholders is mainly seniors and middle-aged because people in such age tend to have a high rate of getting Neuroinflammation. As a team, we have come up with several ways to promote our product.
    According to this plan, we decided to focus on popular science education in the preliminary work. We divide science education into two types. The first is to conduct online publicity activities. We plan to create an official account to increase our publicity. By writing popular science articles every day and our work experience, letting more people know that we are developing a drug that can cure a variety of neurodegenerative diseases with few side effects. Another way is to conduct offline science popularization. Here are two potential offline activities. The first is to conduct charity sales in shopping malls. For this reason, we have customized many gifts with our team logo and put these items in blind boxes for sale. At the same time, we will also invite passers-by to fill out a questionnaire to collect data. Considering how to attract more people to participate in the event, we made roll-up banners and posters. The versatile students in our team also prepared singing and dancing activities. The second way of offline activities is in the community. We will invite elderly people to watch our stage show with knowledge of popular science. And we will also have fun games with the residents and give them free food like eggs and cooking oil. Through the above distributions, I think we will surely let more people know about our drugs.
Safety Concern
    Cytotoxicity should be considered in our future plan.Will the potential implementation of our project involve any cytotoxicity issues? If so, how to tackle these issues? We consider that it is essential for us to verify such issues in our future development. We can not put our project in practice until we fully understand the potential cytotoxicity issues that our project may render.
Future Plan
    In the future, we will continue to improve the performance of drugs, further reduce the side effects of drugs and achieve less dose and greater effect at the same time. With the aggravation of global aging, our drugs will become more popular. At this time, we will strive to develop derivatives centered on neuron target drugs, which can be used to prevent and cure diseases at different stages in the early, middle, and late stages. In addition to form and efficiency, we will vigorously promote the export sales of neuron targets, expand its international influence and help more patients suffering from neurodegenerative diseases around the world.
1) Xu, Ling et al. “Microglia-Mediated Inflammation and Neurodegenerative Disease.” Molecular neurobiology vol. 53,10 (2016): 6709-6715. doi:10.1007/s12035-015-9593-4
2) Voet, Sofie et al. “Microglia in Central Nervous System Inflammation and Multiple Sclerosis Pathology.” Trends in molecular medicine vol. 25,2 (2019): 112-123. doi:10.1016/j.molmed.2018.11.005